Show simple item record

dc.contributor.authorBalmaceda, Nicole
dc.contributor.authorAziz, Muhammad
dc.contributor.authorChandrasekar, Viveksandeep Thoguluva
dc.contributor.authorMcClune, Brian
dc.contributor.authorKambhampati, Suman
dc.contributor.authorShune, Leyla
dc.contributor.authorAbdallah, Al-Ola
dc.contributor.authorAnwer, Faiz
dc.contributor.authorMajeed, Aneela
dc.contributor.authorQazilbash, Muzaffar
dc.contributor.authorGanguly, Siddhartha
dc.contributor.authorMcGuirk, Joseph
dc.contributor.authorMohyuddin, Ghulam Rehman
dc.date.accessioned2021-06-28T16:00:37Z
dc.date.available2021-06-28T16:00:37Z
dc.date.issued2021-06-26
dc.identifier.citationBalmaceda, N., Aziz, M., Chandrasekar, V.T. et al. Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC Cancer 21, 730 (2021). https://doi.org/10.1186/s12885-021-08451-xen_US
dc.identifier.urihttp://hdl.handle.net/1808/31711
dc.descriptionA grant from the One-University Open Access Fund at the University of Kansas was used to defray the author's publication fees in this Open Access journal. The Open Access Fund, administered by librarians from the KU, KU Law, and KUMC libraries, is made possible by contributions from the offices of KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research. For more information about the Open Access Fund, please see http://library.kumc.edu/authors-fund.xml.en_US
dc.description.abstractBackground Patients with multiple myeloma (MM) remain at an increased risk of infection due to the disease process, as well as the ensuing treatments.

Methods We performed a systematic review to evaluate the monthly risk of grade III/IV infection, pneumonia, and neutropenia in patients with myeloma enrolled in randomized clinical trials (RCTs).

Results The risk of grade III or higher infection, pneumonia, and neutropenia persists among all phases of treatment. There was no statistical difference in grade III or higher infection, pneumonia, and neutropenia between frontline and relapsed/refractory setting. In the maintenance setting, the complications of infection, pneumonia, and neutropenia were low, but not negligible. Three-drug regimens were no more likely than two-drug regimens to have an increased risk of Grade III or higher infection.

Conclusions This is the first study to quantify the monthly risk of grade III or higher infection, pneumonia, and neutropenia across different treatment regimens in the frontline, maintenance, and relapsed/refractory settings. The results of our systematic review demonstrate a significant risk for severe infection, pneumonia, and neutropenia in patients with MM. Further studies are needed to determine the value of antibiotic prophylaxis in a broader myeloma patient population, as well as other approaches that will further mitigate the morbidity and mortality related to infection in this vulnerable patient population.
en_US
dc.publisherBMCen_US
dc.rights© The Author(s). 2021. This work is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectMultiple myelomaen_US
dc.subjectProteasome inhibitorsen_US
dc.subjectAnti-CD38en_US
dc.subjectCytotoxic therapyen_US
dc.subjectInfectionen_US
dc.titleInfection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019en_US
dc.typeArticleen_US
kusw.kuauthorBalmaceda, Nicole
kusw.kuauthorShune, Leyla
kusw.kuauthorAbdallah, Al-Ola
kusw.kuauthorGanguly, Siddhartha
kusw.kuauthorMcGuirk, Joseph
kusw.kuauthorMohyuddin, Ghulam Rehman
kusw.kudepartmentKU Medical Centeren_US
dc.identifier.doi10.1186/s12885-021-08451-xen_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2021. This work is licensed under a Creative Commons Attribution 4.0 International License.
Except where otherwise noted, this item's license is described as: © The Author(s). 2021. This work is licensed under a Creative Commons Attribution 4.0 International License.